BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37260079)

  • 1. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy.
    Maggino L; Malleo G; Crippa S; Belfiori G; Bannone E; Lionetto G; Gasparini G; Nobile S; Luchini C; Mattiolo P; Schiavo-Lena M; Doglioni C; Scarpa A; Ferrone C; Bassi C; Fernández-Del Castillo C; Falconi M; Salvia R
    Br J Surg; 2023 Jul; 110(8):973-982. PubMed ID: 37260079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.
    Helm J; Centeno BA; Coppola D; Melis M; Lloyd M; Park JY; Chen DT; Malafa MP
    Cancer; 2009 Sep; 115(18):4080-9. PubMed ID: 19626671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade.
    König AK; Gros H; Hinz U; Hank T; Kaiser J; Hackert T; Bergmann F; Büchler MW; Strobel O
    Eur J Surg Oncol; 2022 Jan; 48(1):113-120. PubMed ID: 34344573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma.
    Malleo G; Maggino L; Nobile S; Casciani F; Cacciatori N; Paiella S; Luchini C; Rusev B; Capelli P; Marchegiani G; Bassi C; Salvia R
    Eur J Surg Oncol; 2020 Sep; 46(9):1734-1741. PubMed ID: 32327367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
    Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
    Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
    Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8
    Chen HY; Wang X; Zhang H; Liu XB; Tan CL
    World J Gastroenterol; 2019 Dec; 25(46):6752-6766. PubMed ID: 31857777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    Ann Surg; 2020 Jun; 271(6):996-1002. PubMed ID: 31895709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
    Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
    Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
    Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
    Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?
    Liu B; Wu J; Li C; Li Y; Qiu H; Lv A; Liu Q; Liu D; Wang Z; Hao C
    Pancreatology; 2022 Jan; 22(1):112-122. PubMed ID: 34764022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
    de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
    J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma.
    Malleo G; Maggino L; Ferrone CR; Marchegiani G; Luchini C; Mino-Kenudson M; Paiella S; Qadan M; Scarpa A; Lillemoe KD; Bassi C; Fernàndez-Del Castillo C; Salvia R
    Ann Surg Oncol; 2020 Oct; 27(10):3898-3912. PubMed ID: 32307617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.